Biologic
Dupilumab outperforms other biologics in asthma outcomes
Patients with asthma and specific eosinophil and IgE levels experienced greater improvements in exacerbations and FEV1 with dupilumab compared with other biologics, according to a study.
Remibrutinib exhibits long-term favorable safety profile for chronic spontaneous urticaria
SAN ANTONIO — Remibrutinib displayed sustained efficacy for chronic spontaneous urticaria with a favorable safety profile over 52 weeks, according to data presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting.
COVID-19 less prevalent among patients with asthma taking biologics
SAN ANTONIO — Patients taking biologics for severe asthma experienced COVID-19 than those who were not taking biologics, according to data presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting.
FDA approves sarilumab as first biologic to treat polymyalgia rheumatica
The FDA has approved sarilumab for the treatment of polymyalgia rheumatica in adults who have experienced an inadequate response to, or cannot taper, corticosteroids, according to a press release from Sanofi.
Biologics reduce exacerbations among patients with asthma, allergic rhinitis
SAN ANTONIO — Patients with severe asthma and allergic rhinitis experienced fewer exacerbations after taking a biologic for 6 months, with greater decreases seen for biologics other than omalizumab, according to the CHRONICLE study.
Garadacimab significantly reduces hereditary angioedema attack rates
SAN ANTONIO — Garadacimab significantly reduced attack rates among patients with hereditary angioedema and was well tolerated, according to an abstract presented at the American Academy of Allergy, Asthma & Immunology Annual meeting.
FDA approves expanded use of Takhzyro for children with hereditary angioedema
The FDA has approved a supplemental biologics license application to expand the use of lanadelumab-flyo for prophylaxis of hereditary angioedema attacks in children aged 2 to younger than 12 years, according to a press release.
Male providers more likely to prescribe biologic immune modifiers, oral small molecules
Men, along with clinicians with more than 4 years’ experience, were more likely than women and less experienced providers to prescribe oral small molecule medications and biologic immune response modifiers, according to a study.
Hooked on Rheum with John R.P. Tesser, MD
Searching for a future discipline to pursue during my time in medical school at the University of Rochester in New York, I grappled with family medicine, psychiatry and neurology.
VIDEO: Switching biologics ‘irrationally’ may be associated with worse asthma outcomes
In this Healio video exclusive, Nicola A. Hanania, MD, MS, highlights presentations from the CHEST Annual Meeting discussing biologic choice — particularly tezepelumab — in patients with severe asthma.